Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
BG Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, 112, 2261, 10.1182/blood-2007-12-128843
MA Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat Med, 14, 1264, 10.1038/nm.1882
RA Morgan, 2010, Adoptive cell therapy: genetic modification to redirect effector cell specificity, Cancer J, 16, 336, 10.1097/PPO.0b013e3181eb3879
JN Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931
M Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842
RJ Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540
JN Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
O’Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, <etal>et al</etal>.. (2012) Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Scientific Reports 2. DOI: 10.1038/srep00249.
IC Nicholson, 1997, Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma, Mol Immunol, 34, 1157, 10.1016/S0161-5890(97)00144-2
CH June, 2009, Engineering lymphocyte subsets: tools, trials and tribulations, Nat Rev Immunol, 9, 704, 10.1038/nri2635
RA Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003
H Singh, 2008, Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system, Cancer Res, 68, 2961, 10.1158/0008-5472.CAN-07-5600
PV Manuri, 2009, piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies, Hum Gene Ther, 21, 427, 10.1089/hum.2009.114
PB Hackett, 2010, A transposon and transposase system for human application, Mol Ther, 18, 674, 10.1038/mt.2010.2
H Singh, 2011, Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies, Cancer Res, 71, 3516, 10.1158/0008-5472.CAN-10-3843
H Torikai, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365
Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, <etal>et al</etal>.. (2012) Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood. J Vis Exp doi:10.3791/50070.
M Whitlow, 1993, An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability, Protein Engineering, 6, 989, 10.1093/protein/6.8.989
DL Porter, 2011, Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, New England Journal of Medicine, 365, 725, 10.1056/NEJMoa1103849
Q Ma, 2004, Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy, Prostate, 61, 12, 10.1002/pros.20073
M Moeller, 2005, Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection, Blood, 106, 2995, 10.1182/blood-2004-12-4906
B Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J Clin Invest, 121, 1822, 10.1172/JCI46110
CM Kowolik, 2006, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells, Cancer Res, 66, 10995, 10.1158/0008-5472.CAN-06-0160
JR Park, 2007, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma, Mol Ther, 15, 825, 10.1038/sj.mt.6300104
CH Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520
A Hombach, 2010, Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response, Gene Ther, 17, 1206, 10.1038/gt.2010.91
B Jena, 2010, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, 116, 1035, 10.1182/blood-2010-01-043737
C Rossig, 2001, Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes, Int J Cancer, 94, 228, 10.1002/ijc.1457
C Rossig, 2002, Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy, Blood, 99, 2009, 10.1182/blood.V99.6.2009
J Vera, 2006, T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells, Blood, 108, 3890, 10.1182/blood-2006-04-017061